The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization

European Neuropsychopharmacology

Volumn 20, Issue 7, 2010, Pages 501-508

  Velazquez Sanchez C ^a   Ferragud, A ^a   Murga, J ^b   Carda M ^b   Canales, J J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITAT JAUME I   (Spain)

Author keywords

Anxiety; Benztropine analogues; Cocaine; Locomotor activity; Place preference; Sensitization

Indexed keywords

DOPAMINE UPTAKE INHIBITOR; JHW 007; N (N BUTYL) 3ALPHA [BIS(4' FLUOROPHENYL)METHOXY]TROPANE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ANXIETY DISORDER; ARTICLE; AVERSION; BINDING AFFINITY; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; HYPERACTIVITY; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; SENSITIZATION; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZTROPINE; COCAINE; CONDITIONING, OPERANT; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; REWARD;

EID: 77953355881     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.03.005     Document Type: Article

References (40)

1. Agoston G.E., Wu J.H., Izenwasser S., George C., Katz J., Kline R.H., et al. Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J. Med. Chem. 1997, 40:4329-4339.
2. Beuming T., Kniazeff J., Bergmann M.L., Shi L., Gracia L., Raniszewska K., et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 2008, 11:780-789.
3. Biala G., Kruk M. Amphetamine-induced anxiety-related behavior in animal models. Pharmacol. Rep. 2007, 59:636-644.
4. Dazzi L., Spiga F., Pira L., Ladu S., Vacca G., Rivano A., et al. Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. J. Neurochem. 2001, 76:1212-1220.
5. Desai R.I., Kopajtic T.A., Koffarnus M., Newman A.H., Katz J.L. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 2005, 25:1889-1893.
6. Ferragud A., Velazquez-Sanchez C., Hernandez-Rabaza V., Nacher A., Merino V., Carda M., et al. A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat. Psychopharmacology (Berl) 2009, 207:281-286.
7. Gorelick D.A., Gardner E.L., Xi Z.X. Agents in development for the management of cocaine abuse. Drugs 2004, 64:1547-1573.
8. Grabowski J., Roache J.D., Schmitz J.M., Rhoades H., Creson D., Korszun A. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 1997, 17:485-488.
9. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 2004, 29:1439-1464.
10. Hiranita T., Soto P.L., Newman A.H., Katz J.L. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J. Pharmacol. Exp. Ther. 2009, 329:677-686.
11. Huang X., Zhan C.G. How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys. J. 2007, 93:3627-3639.
12. Indarte M., Madura J.D., Surratt C.K. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. Proteins 2008, 70:1033-1046.
13. Jain N.S., Hirani K., Chopde C.T. Reversal of caffeine-induced anxiety by neurosteroid 3-alpha-hydroxy-5-alpha-pregnane-20-one in rats. Neuropharmacology 2005, 48:627-638.
14. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., et al. New treatments for cocaine dependence: a focused review. Int. J. Neuropsychopharmacol. 2008, 11:425-438.
15. Katz J.L., Newman A.H., Izenwasser S. Relations between heterogeneity of dopamine transporter binding and function and the behavioral pharmacology of cocaine. Pharmacol. Biochem. Behav. 1997, 57:505-512.
16. Li S.M., Newman A.H., Katz J.L. Place conditioning and locomotor effects of N-substituted, 4', 4"-difluorobenztropine analogs in rats. J. Pharmacol. Exp. Ther. 2005, 313:1223-1230.
17. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
18. McCullough L.D., Salamone J.D. Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens. Psychopharmacology (Berl) 1992, 109:379-382.
19. Minozzi S., Amato L., Davoli M., Farrell M., Lima Reisser A.A., Pani P.P., et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst. Rev. 2008, CD006754.
20. Moghaddam B., Roth R.H., Bunney B.S. Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum. Neuroscience 1990, 36:669-676.
21. Muller C.P., Carey R.J., Wilkisz M., Schwenzner S., Jocham G., Huston J.P., et al. Acute anxiolytic effects of cocaine: the role of test latency and activity phase. Pharmacol. Biochem. Behav. 2008, 89:218-226.
22. Newman A.H., Agoston G.E. Novel benztropine [3a-(diphenylmethoxy)tropane] analogs as probes for the dopamine transporter. Curr. Med. Chem. 1998, 5:305-319.
23. Newman A.H., Katz J.L. Atypical dopamine uptake inhibitors that provide clues about cocaine's mechanism at the dopamine transporter. Top. Med. Chem. 2009, 4:95-129.
24. Newman A.H., Kulkarni S. Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic-a focus on analogues of benztropine and rimcazole. Med. Res. Rev. 2002, 22:429-464.
25. Orson F.M., Kinsey B.M., Singh R.A., Wu Y., Kosten T.R. Vaccines for cocaine abuse. Hum. Vaccin. 2009, 5:194-209.
26. Preti A. Vanoxerine National Institute on Drug Abuse. Curr. Opin. Investig. Drugs 2000, 1:241-251.
27. Raje S., Dowling T.C., Eddington N.D. Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 768:305-313.
28. Raje S., Cornish J., Newman A.H., Cao J., Katz J.L., Eddington N.D. Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm. Res. 2005, 22:603-612.
29. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
30. Rothman R.B. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci. 1990, 46:L17-L21.
31. Rothman R.B., Baumann M.H., Prisinzano T.E., Newman A.H. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem. Pharmacol. 2008, 75:2-16.
32. Simon P., Panissaud C., Costentin J. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine. Psychopharmacology (Berl) 1994, 114:597-600.
33. Sofuoglu M., Kosten T.R. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin. Emerg. Drugs 2006, 11:91-98.
34. Tanda G., Newman A., Ebbs A.L., Tronci V., Green J., Tallarida R.J., et al. Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J. Pharmacol. Exp. Ther. 2009, 330:802-809.
35. Velazquez-Sanchez C., Ferragud A., Hernandez-Rabaza V., Nacher A., Merino V., Carda M., et al. The dopamine uptake inhibitor 3-[bis(4'-fluorophenyl) metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward. Neuropsychopharmacology 2009, 34:2497-2507.
36. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Ding Y.S., Logan J., et al. Relationship between psychostimulant-induced and high and dopamine transporter occupancy. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10388-10392.
37. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386:827-830.
38. Volkow N.D., Fowler J.S., Wang G.J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J. Psychopharmacol. 1999, 13:337-345.
39. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc. 2007, 2:322-328.
40. Yang X.M., Gorman A.L., Dunn A.J., Goeders N.E. Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol. Biochem. Behav. 1992, 41:643-650.